These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10426302)

  • 1. COX-2: promoting tolerance.
    Morteau O
    Nat Med; 1999 Aug; 5(8):867-8. PubMed ID: 10426302
    [No Abstract]   [Full Text] [Related]  

  • 2. T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation.
    Brewer JA; Khor B; Vogt SK; Muglia LM; Fujiwara H; Haegele KE; Sleckman BP; Muglia LJ
    Nat Med; 2003 Oct; 9(10):1318-22. PubMed ID: 12949501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
    Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
    Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha.
    Stamp LK; Cleland LG; James MJ
    J Rheumatol; 2004 Jul; 31(7):1246-54. PubMed ID: 15229940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paracrine upregulation of monocyte cyclooxygenase-2 by mediators produced by T lymphocytes: role of interleukin 17 and interferon-gamma.
    Stamp LK; James MJ; Cleland LG
    J Rheumatol; 2004 Jul; 31(7):1255-64. PubMed ID: 15229941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
    Sharma S; Yang SC; Zhu L; Reckamp K; Gardner B; Baratelli F; Huang M; Batra RK; Dubinett SM
    Cancer Res; 2005 Jun; 65(12):5211-20. PubMed ID: 15958566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma/delta T cells in celiac disease: friend or foe?
    Splawski J
    J Pediatr Gastroenterol Nutr; 1992 Aug; 15(2):217-8. PubMed ID: 1403476
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.
    Sennlaub F; Valamanesh F; Vazquez-Tello A; El-Asrar AM; Checchin D; Brault S; Gobeil F; Beauchamp MH; Mwaikambo B; Courtois Y; Geboes K; Varma DR; Lachapelle P; Ong H; Behar-Cohen F; Chemtob S
    Circulation; 2003 Jul; 108(2):198-204. PubMed ID: 12821538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
    Xu H; Izon DJ; Loftin C; Spain LM
    Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction.
    Doré S; Otsuka T; Mito T; Sugo N; Hand T; Wu L; Hurn PD; Traystman RJ; Andreasson K
    Ann Neurol; 2003 Aug; 54(2):155-62. PubMed ID: 12891667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.
    Klein RD; Van Pelt CS; Sabichi AL; Dela Cerda J; Fischer SM; Fürstenberger G; Müller-Decker K
    Cancer Res; 2005 Mar; 65(5):1808-13. PubMed ID: 15753378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between two strains of myelin basic protein (MBP) TCR transgenic mice: implications for tolerance induction.
    Song F; Wardrop RM; Gienapp IE; Stuckman SS; Goverman J; Whitacre CC
    J Autoimmun; 2002 Feb; 18(1):27-37. PubMed ID: 11869044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell tolerance and autoimmunity.
    Abbas AK; Lohr J; Knoechel B; Nagabhushanam V
    Autoimmun Rev; 2004 Nov; 3(7-8):471-5. PubMed ID: 15546793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor).
    Poon R; Smits R; Li C; Jagmohan-Changur S; Kong M; Cheon S; Yu C; Fodde R; Alman BA
    Oncogene; 2001 Jan; 20(4):451-60. PubMed ID: 11313976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor.
    Saito T; Rodger IW; Shennib H; Hu F; Tayara L; Giaid A
    Can J Physiol Pharmacol; 2003 Feb; 81(2):114-9. PubMed ID: 12710523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?
    Crentsil V
    Med Hypotheses; 2005; 65(1):97-102. PubMed ID: 15893125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
    König JE; Senge T; Allhoff EP; König W
    Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.
    Kundu N; Fulton AM
    Cancer Res; 2002 Apr; 62(8):2343-6. PubMed ID: 11956094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human lupus T cells resist inactivation and escape death by upregulating COX-2.
    Xu L; Zhang L; Yi Y; Kang HK; Datta SK
    Nat Med; 2004 Apr; 10(4):411-5. PubMed ID: 14991050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.